CRISPR Therapeutics AG (CRSP) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-02-12
Business type: Asset play
How it makes money
It generates income through a co-development agreement for CASGEVY, sharing profits and costs for the first approved CRISPR-based gene therapy for hemoglobinopathies.
The company relies on its partnership for CASGEVY, a one-time treatment for sickle cell disease and beta thalassemia. While it shares global costs with its partner, earnings depend on converting an estimated 60,000 addressable patients into treated cases across the United States, Europe, and the Middle East.
Profitability is driven by milestone payments and the eventual capture of a share of commercial revenue, though the business currently expects expenses to exceed its share of revenue.
What protects it: the moat
It defends its market position through exclusive CRISPR/Cas9 intellectual property based on Nobel Prize-winning technology that allows for precise double-strand DNA breaks.
The business holds a foundational patent estate for CRISPR/Cas9, which it claims is more predictable and straightforward to engineer than rival systems like ZFNs or TALENs. This technological moat is reinforced by being the first to receive regulatory approval for a CRISPR-based medicine, establishing a first-mover advantage in gene-edited cell therapy.
What growth costs
It maintains an internal GMP manufacturing facility in Framingham and must fund its full share of CASGEVY program costs starting in 2025.
The company invests heavily in its internal CAR T pipeline, specifically producing zugo-cel for clinical trials at its Massachusetts facility.
Financially, the business faces a transition in 2025; it can no longer defer CASGEVY program costs, requiring it to utilize its $1,975.8 million cash balance to fund commercialization and development that currently exceeds its revenue share.
What could damage it
The company faces permanent impairment if rival lentiviral gene therapies, which also offer curative potential for blood disorders, capture the limited addressable patient population.
While CRISPR offers precise editing, competitors like Genetix Biotherapeutics have already secured approvals for lentiviral therapies such as Lyfgenia and Zynteglo. These rival platforms target the same 60,000 patients and represent a direct threat to the company's ability to achieve commercial scale, especially if they demonstrate superior safety or fewer regulatory warnings.
About CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.